Ceramides: A Comprehensive Reference
1. Identity: Chemical and Botanical Overview
Chemical Definition and Nomenclature
Ceramides (abbreviated Cer) are a structurally diverse class of sphingolipids — lipid molecules built on a sphingoid long-chain base backbone. Ceramides are chemically composed of long-chain sphingoid bases linked with free fatty acids via an amide bond. Sphingolipids are a family of compounds that have a sphingoid base with an amide-linked fatty acid and a polar head group, such as phosphorylcholine (for sphingomyelin) or carbohydrate (for cerebrosides, gangliosides, and other complex glycolipids).
The heterogeneity of ceramides is immense. Ceramides are a structurally heterogeneous and complex group of sphingolipids containing derivatives of sphingosine bases in amide linkage with a variety of fatty acids. Differences in chain length, type and extent of hydroxylation, saturation, etc. are responsible for the heterogeneity of the epidermal sphingolipids.
A systematic nomenclature has been developed for human skin ceramides. A nomenclature using a combination of abbreviations for types of sphingoid bases — dihydrosphingosine [DS], sphingosine [S], and phytosphingosine [P] — and fatty acids — non-hydroxy fatty acid [N], α-hydroxy fatty acid [A], and esterified ω-hydroxy fatty acid [EO] — has been proposed to discriminate the epidermal ceramide classes. Ceramides represent the major lipid class by mass (~50%) and have diverse molecular structures that are classified into 12 subclasses in human stratum corneum. In addition to those subclasses, there is a further subdivision according to the carbon chain length, resulting in approximately 480 types of ceramide reported to exist in human stratum corneum.
Among the known subclasses in the human stratum corneum, quantitative profiling by liquid chromatography-mass spectrometry has revealed a distinct compositional hierarchy. Human stratum corneum is composed of CER[NP] (22.1%), CER[NH] (14.5%), CER[AH] (10.8%), CER[NDS] (9.8%), CER[AS] (9.6%), CER[AP] (8.8%), CER[NS] (7.4%), CER[EOS] (6.5%), CER[EOH] (4.3%), and CER[ADS] (1.6%), among others. EO ceramides are epidermis-specific ceramide classes, and their characteristic EO structure is important for the formation and stabilization of lipid organization in the lipid lamellae.
Natural Sources
Ceramides are found across a wide spectrum of biological kingdoms. Many ceramides are naturally occurring in certain plant tissues such as yeast, and also in the mammalian stratum corneum and in other mammalian tissues such as brain tissue and nervous tissue. Bovine brain tissue and human spleen tissue are common commercial sources.
In the plant kingdom, ceramides take a specific form. The most abundant class of sphingolipids in plant tissue are mono-glucosylceramides, which are mostly characterized by a double bond at position 8 on the sphingoid residues and α-hydroxy fatty acids. Phytoceramides are plant-derived ceramides found in wheat, rice, and sweet potatoes. Additional dietary sources include corn, soybean, and konjac. Glucosyl-ceramides are present in plant foods and are considered to be very important for skin health.
The primary dietary source of sphingolipid comes from plants, especially cereals, which by themselves represent an average intake of 76 mg/day, corresponding to more than 25% of the total daily sphingolipid consumption.
Common Supplement Forms and Preparations
In the dietary supplement and cosmetic industries, ceramides are prepared and administered in several forms:
- Phytoceramides (plant-derived, oral): In their natural plant form, phytoceramides exist as glucosylceramides (GlcCer) — ceramides with a glucose molecule at the head group — rather than as free ceramides. The most extensively studied commercial extract is a wheat-derived preparation (sold under the brand name Lipowheat), as well as rice-derived and konjac-derived glucosylceramide concentrates.
- Topical ceramide formulations: In the cosmetic industry, ceramides are used for skin barrier repair and moisturization. However, their poor water solubility necessitates the development of effective delivery systems.
- Animal-derived ceramide types: A mixture termed "ceramides type III" is prepared by the action of phospholipase C on bovine brain sphingomyelin; "ceramides type IV" is similar but contains α-hydroxy acids rather than stearic and nervonic acids.
- Synthetic ceramides: Skin-identical synthetic ceramides are used topically as alternatives to natural extracts, frequently formulated in a physiological ratio with cholesterol and free fatty acids.
2. Traditional and Historical Use
Unlike many botanical supplements with centuries-old formal traditions, ceramides were not recognized as distinct biochemical entities until the late 19th century, when German chemist J.L.W. Thudichum isolated and characterized sphingolipids from brain tissue in the 1870s and 1880s — naming them for their "sphinx-like" enigmatic chemistry. Ceramides specifically were not identified as a named subclass of sphingolipids until the 20th century, and formal scientific characterization of their role in the skin barrier progressed primarily in the 1970s through 1990s.
As such, ceramides do not carry a documented traditional herbal medicine usage in the way that botanical preparations such as ginseng or valerian do. Their presence in dietary staples — wheat, rice, sweet potatoes, corn — means that human populations have consumed glucosylceramides as normal components of diet throughout history, but without specific pharmacological intent or preparation. The modern understanding of ceramides as a therapeutic or supplementary ingredient is entirely a product of 20th- and 21st-century biochemistry and clinical nutrition science, beginning with studies of their structural role in epidermal barrier function in the 1970s–1990s and followed by clinical supplementation trials from roughly 2000 onward.
Glucosyl-ceramides are the precursors of gangliosides, which are known to be important for brain development. Dietary gangliosides are known to increase the ganglioside accumulation in brain and other parts of the nervous system as early as age two to four. Interest in dietary ceramides and gangliosides for infant nutrition has followed from this understanding.
3. Key Constituents, Chemical Classes, and Mechanisms of Action
Structural Diversity
Ceramides belong to the sphingolipid family and are formed by combining a saturated fatty acid, namely palmitate, with sphingosine via an amide bond. There is a diversity of ceramide species, reflecting the existence of six isoforms of ceramide synthase located in the endoplasmic reticulum. These are classified according to the length of the fatty acid chain linked to sphingosine.
Biosynthesis Pathways
Ceramides are produced endogenously by three distinct biochemical pathways:
- De novo synthesis: De novo biosynthesis occurs in the cytosolic leaflet of the smooth endoplasmic reticulum where serine palmitoyltransferase (SPT) catalyzes the first and rate-limiting step — the decarboxylation of palmitoyl-CoA with L-serine to generate 3-ketosphinganine. Fatty acids are then converted to ceramide via a series of reactions by serine palmitoyltransferase, 3-ketosphinganine reductase, ceramide synthase, and dihydroceramide desaturase.
- Sphingomyelin hydrolysis pathway: The degradation of sphingomyelins by sphingomyelinases takes place in different sub-compartments, including the plasma membrane, mitochondria, lysosomes, and Golgi apparatus.
- Salvage pathway: The salvage pathway generates ceramides from complex sphingolipids in lysosomes or endosomes.
Ceramidase converts ceramide into sphingosine, which in turn is phosphorylated to sphingosine-1-phosphate (S1P) by sphingosine kinase 1 or 2. This ceramide/S1P metabolic rheostat is of broad physiological importance.
Skin Barrier Mechanism
Synthesized ceramides are eventually assembled into a lamellar structure filling the spaces between cells and creating a lipid-containing membrane that maintains competent skin barrier function. The lamellar bodies (also called Odland bodies) of the upper epidermis package and secrete ceramides into the extracellular space of the stratum corneum. The stratum corneum consists of a lipid matrix and 15–20 layers of flattened dead cells (corneocytes) embedded in this lipid matrix. This structure, with 10–20 µm in thickness, is called a "brick and mortar" model and constitutes a major barrier function of the stratum corneum.
Intercellular lipids are principally composed of three classes of substances: ceramides, cholesterol, and free fatty acids. Ceramides, as core lipid components, exert their functions through two primary mechanisms: (1) establishing a hydrophobic barrier to reduce excessive water evaporation, maintaining the dermal-epidermal moisture gradient essential for normal skin metabolism; and (2) constructing a selective permeability barrier.
Multiple clinical and experimental studies found different classes of ceramide species to affect the skin barrier nonuniformly, with some ceramides being associated with an impaired skin barrier, such as ceramide NS, while others are associated with a healthy, unimpaired skin, e.g., ceramide NP.
Cellular Signaling Functions
Beyond their structural roles, ceramides function as potent bioactive signaling molecules. Bioactive sphingolipids — ceramide, sphingosine, and their respective 1-phosphates (C1P and S1P) — are signaling molecules serving as intracellular second messengers. Ceramides promote epidermal self-renewal and regulate skin immune responses.
Ceramide, the precursor of all complex sphingolipids, is a potent signaling molecule that mediates key events of cellular pathophysiology. In the nervous system, sphingolipid metabolism has an important impact. Sphingolipids are abundant on neural cellular membranes and represent potent regulators of brain homeostasis. Ceramide intracellular levels are fine-tuned, and alteration of the sphingolipid–ceramide profile contributes to the development of age-related, neurological, and neuroinflammatory diseases.
Oral Absorption and Bioavailability of Supplemental Ceramides
The absorption of plant-derived glucosylceramides differs from free ceramides. The glucosylated form is what makes phytoceramides orally bioavailable: the glucose attachment enables intestinal absorption through pathways unavailable to free ceramides, making phytoceramides one of the few genuinely evidence-supported routes to influencing skin ceramide status from within. Ingested glucosylceramides are partially hydrolysed by ceramidases in the small intestinal mucosa, releasing sphingosine, phytosphingosine, and fatty acid metabolites into portal circulation. Dietary ceramides are absorbed, processed in the liver, transported to the skin via lipoproteins, and incorporated into the stratum corneum lamellar structures.
4. Scientific Evidence by Area of Use
4.1 Skin Hydration and Barrier Function
Overview of Clinical Evidence
This is the most thoroughly investigated area for oral ceramide supplementation. Among dietary supplements studied in clinical RCTs for skin health, ceramides were the third most frequently investigated category, being studied in 11 out of 66 randomized controlled trials identified in one systematic review.
A 2022 systematic review and meta-analysis published in Frontiers in Nutrition — drawing from PubMed, Embase, and the Cochrane Library covering January 2000 to November 2021 — evaluated 66 RCTs across multiple skin supplement categories. Oral collagen or ceramide resulted in a statistically significant increase in skin hydration and a decrease in transepidermal water loss (TEWL) compared to placebo. All food supplements were found to be safe throughout the research (normally ≤24 weeks).
A separate meta-analysis specifically targeting oral ceramide studies corroborated these findings: a meta-analysis of seven clinical studies on oral ceramide intake revealed a significant increase in skin hydration and a decrease in TEWL compared to placebo.
Individual RCTs — Wheat-Derived Ceramides
One randomized, double-blind, placebo-controlled study evaluated the skin hydration benefits of a branded wheat phytoceramide extract (Lipowheat). A total of 51 women (aged 20–63) with dry or very dry skin were given WEO (350 mg) or placebo daily for 3 months. The ceramide group experienced improvements in skin hydration, and tended to have decreased dryness and redness. The researchers concluded that "a significant increase in skin hydration and an improvement in associated clinical signs were observed in women with dry skin."
A further placebo-controlled clinical study investigated a wheat polar lipid complex (WPLC) containing glucosylceramides. Sixty volunteers presenting dry and wrinkled skin were supplemented for 60 days with either a placebo or a WPLC extract in oil or powder form (1.7 mg GluCers and 11.5 mg of digalactosyldiglycerides). Oral intake of WPLC significantly increased skin hydration (p < 0.001), elasticity, and smoothness (p < 0.001), and decreased TEWL (p < 0.001), roughness (p < 0.001), and wrinkledness (p < 0.001) in both WPLC groups compared to placebo.
Individual RCTs — Wine Lees–Derived Ceramides
A 2024 randomized, double-blind, placebo-controlled study published in Nutrients examined ceramides and glucosylceramides extracted from wine lees. The primary outcome was TEWL; secondary outcomes included skin hydration, visual analog scale of itching, and the Japanese Skindex-29. With 29 subjects in the final analysis (placebo n=15; test n=14), the test group showed a tendency of lower TEWL after 8 weeks (p=0.07) and significantly lower TEWL after 12 weeks of administration (p=0.04). No significant differences were observed in the secondary outcome parameters, and no adverse events related to the supplements were reported.
Individual Studies — Rice-Derived Ceramides
An open-label prospective study published in Nutrients (2022) examined rice ceramide (RC) supplementation in 50 volunteers. The study aimed to evaluate the efficacy of rice ceramides supplementation to improve skin barrier function and as a depigmenting agent. It investigated the beneficial effects of orally administered RC supplementation in 50 voluntary participants, assessing skin hydration, firmness and elasticity, transepidermal water loss, melanin index, erythema index, sebum production, pH, and wrinkle severity at baseline and during monthly follow-up visits. Separately, a 12-week study using 1.8 mg daily of rice-derived glucosylceramides showed 31.9% hydration improvement on the arm and 22.8% on the cheek.
Atopic Dermatitis — Konjac Ceramides
A controlled study examined the effects of oral phytoceramide on atopic dermatitis (eczema) in children. A total of 50 children with moderate eczema and allergies to house dust mites were given milk sugar, or milk sugar with 1.8 mg konjac ceramide daily for 2 weeks. Ingestion of konjac ceramides showed positive effects in atopic dermatitis patients as well as healthy volunteers, with results showing improved skin symptoms and reduced skin allergic responses.
Topical Ceramide Evidence — Atopic Dermatitis
The topical ceramide evidence base is more extensive than the oral. A decrease in the ceramide content of the stratum corneum is known to cause dry and barrier-disrupted skin. A literature review evaluated the clinical usefulness of preparations containing natural or synthetic ceramides for water retention and barrier functions. Among 41 comparative controlled studies reviewed, 12 were selected using strict patient, intervention, comparison, and outcome criteria. These 12 reports showed that external ceramide-containing preparations can improve dry skin and barrier function in patients with atopic dermatitis.
Animal studies showed that although topical application of ceramide alone delayed barrier recovery, lipid mixtures of ceramides, cholesterol, and free fatty acids accelerated barrier recovery. Subsequently, a ceramide-dominant lipid mixture with a 3:1:1 molar ratio was shown to be ideal for barrier restoration. Several clinical studies have shown that ceramide-dominant emollients represent a safe and useful adjunct to AD treatment. Many other studies have shown the beneficial effects of ceramide-containing emollients on skin condition in xerosis and AD.
Evidence Strength Assessment — Skin/Topical
Topical ceramide formulations for atopic dermatitis and dry skin are supported by multiple controlled trials and are considered an established adjunctive therapy. Oral ceramide supplementation for skin hydration and TEWL improvement is supported by a growing body of RCTs and two meta-analyses, but most individual trials involve small sample sizes (studies remain limited and predominantly involve small sample sizes), and effect sizes are meaningful but modest. The evidence for oral ceramides on skin outcomes is best characterized as moderate and promising, not yet definitive.
4.2 Aging Skin
Ceramide depletion is an established feature of skin aging. The content of skin ceramides declines with skin aging, reducing up to 30% of total skin lipid profile compared to young stratum corneum. An age-dependent decrease in ceramide content correlates with cutaneous clinical signs of dryness, loss of elasticity, and increased roughness. Research and clinical teams have investigated potential changes in the level and arrangement of inter-corneocyte lipids in normal skin and when skin is exposed to different external or internal stressors such as cold, UV light, aging, or during chronic inflammatory skin diseases. The clinical trials described above in §4.1 predominantly recruited older adult participants with dry or aging skin, and their outcomes — improved hydration, elasticity, and reduced wrinkles — are directly relevant to skin aging. Evidence in this area is consistent but is largely derived from trials focused on barrier function rather than pure anti-aging endpoints.
4.3 Atopic Dermatitis and Psoriasis
Atopic dermatitis (AD) is a common chronic skin disease associated with skin barrier dysfunction and immunological abnormalities. In patients with AD, the amount and composition of ceramides in the stratum corneum are altered. This suggests that ceramide abnormalities are involved in the pathogenesis of AD. The mechanism underlying lipid abnormalities in AD has not yet been fully elucidated, but the involvement of Th2 and Th1 cytokines is implicated.
Cytokines dysregulate ceramide synthesis directly. The precise mechanisms by which cutaneous inflammation alters the ceramide profile of the stratum corneum are not fully known, but various cytokines that are increased during inflammation have effects on fatty acid elongation and ceramide synthesis. For example, in human keratinocytes, interferon gamma decreased the expression of elongases of long-chain fatty acids and ceramide synthase 3; IL-4/IL-13 inhibit elongase 3 and 6 expression in keratinocyte cultures; and TNF-alpha, IL-1 beta, IL-6, and IL-33 inhibited elongase 3 in keratinocyte cultures.
In psoriasis, a parallel picture emerges. Alterations in ceramide composition — an increase in short-chain and a decrease in long-chain ceramides — and concomitant decreases in skin barrier function are observed in psoriasis and are similar to the abnormalities observed in atopic dermatitis. CER[EOS], CER[NP], and CER[AP] levels were found to be decreased in psoriatic patients.
Evidence for oral ceramides specifically for psoriasis in human clinical trials remains limited. Psoriatic skin is ceramide-depleted, though clinical trials of oral ceramides specifically for psoriasis are limited.
4.4 Cardiovascular and Metabolic Disease
The relationship between ceramide levels and cardiometabolic disease is an active and clinically important area of research. Ceramides are bioactive sphingolipids increasingly recognized as mediators of cardiometabolic disease and residual cardiovascular risk. Accumulating evidence from experimental and clinical studies indicates that specific ceramide species contribute to insulin resistance, endothelial dysfunction, myocardial injury, and adverse cardiovascular outcomes.
Specific ceramide species have opposite risk associations. In particular, long-chain ceramides (C16:0, C18:0, C20:0 Cer) are consistently associated with myocardial infarction, heart failure, and cardiovascular mortality, whereas very-long-chain ceramides (C22:0, C24:0 Cer) exhibit neutral or potentially protective associations.
Ceramides are components of sphingolipid metabolism and have been linked to cardiovascular disease (CVD) risk factors, including hypertension, insulin resistance, dyslipidemia, and chronic kidney disease. Regulation of ceramide levels under pathological conditions, including myocardial infarction, hypertension, and atherosclerosis, has drawn great attention. Increased ceramide levels are strongly associated with adverse cardiovascular risks and events while inhibiting the synthesis of ceramide or accelerating its degradation improves a variety of cardiovascular diseases.
These mechanisms are linked to the development of metabolic and cardiovascular diseases, including obesity, type 2 diabetes mellitus, metabolic dysfunction-associated steatotic liver disease, stroke, atherosclerotic cardiovascular disease, chronic kidney disease, coronary artery disease, myocardial infarction, and heart failure. Importantly, ceramide risk scores such as CERT1 and CERT2 have been developed as clinical tools. The clinical utility of ceramide risk scores, such as CERT 1/2, which enhance risk stratification for major adverse cardiovascular events and guide precision therapy development, are under examination.
Evidence strength: Evidence in this area is predominantly mechanistic, observational (biomarker studies), and experimental (animal/in vitro). The ceramide-CVD association is well established in clinical observational data, but the use of oral ceramide supplementation as a therapeutic intervention for cardiovascular disease in humans has not been established through RCTs. This field is focused on ceramide inhibition (reducing harmful ceramide species) rather than supplementation.
4.5 Insulin Resistance and Type 2 Diabetes
Ceramide species, particularly the long-chain C18:0 and C16:0-ceramides, have been proposed to be important mediators of lipotoxicity. In obesity, ceramide species can accumulate in insulin-sensitive tissues and in β-cells. Controlling for obesity, diagnosis of type 2 diabetes correlated with increased sphingolipids, dihydroceramides, and ceramides (total and C16:0). Dihydroceramides were elevated in patients up to nine years prior to their diabetes diagnosis, demonstrating the value of dihydroceramides as an early sign of metabolic dysfunction.
Work by Summers and colleagues shows that ceramide production is an important factor in the development of insulin resistance through glucocorticoids and saturated fatty acids, but not through unsaturated fatty acids. Women with polycystic ovarian syndrome showed 25% reduced whole-body insulin sensitivity and 40% lower circulating adiponectin levels. Importantly, their skeletal muscle showed a 300% increase in ceramide levels, further underlining the inverse relationship between circulating adiponectin and ceramide levels.
Evidence strength: Evidence is primarily from observational and mechanistic studies, with ceramides positioned as biomarkers and potentially causal mediators of insulin resistance rather than therapeutic targets for oral supplementation. RCT evidence for oral ceramide supplementation in metabolic disease is lacking.
4.6 Neurological Function and Neurodegenerative Disease
In the nervous system, sphingolipid metabolism has an important impact. Neurons are polarized cells, and their normal functions — such as neuronal connectivity and synaptic transmission — rely on selective trafficking of molecules across the plasma membrane. Sphingolipids are abundant on neural cellular membranes and represent potent regulators of brain homeostasis.
Accumulating evidence points to sphingolipids' engagement in brain aging and in neurodegenerative disorders such as Alzheimer's, Parkinson's, and Huntington's diseases and amyotrophic lateral sclerosis. Metabolic alterations observed in the course of neurodegeneration favor ceramide-dependent pro-apoptotic signaling, while the levels of the neuroprotective S1P are reduced. These trends are observed early in the diseases' development, suggesting a causal relationship.
Mechanistic evidence has shown links between altered ceramide/S1P balance and the production, secretion, and aggregation of amyloid β/α-synuclein as well as signaling pathways of critical importance for the pathomechanism of protein conformation diseases.
Several studies support the role of ceramide in inducing cellular senescence and in activating genetic/biochemical pathways involved with aging. Accumulation of ceramide occurs normally during development and aging in single cells, and young cells treated with exogenous ceramide exhibit a senescent-like phenotype.
Evidence strength: Evidence is entirely preclinical (in vitro, animal models, and post-mortem human tissue analysis) with respect to neurological supplementation or intervention. No human clinical trials of oral ceramide supplementation for neurodegenerative disease have been identified. The neurological ceramide literature is mechanistic and largely describes ceramide as a disease biomarker and pathological mediator rather than a therapeutic ingredient.
4.7 Cerebrovascular Disease
Ceramide, a bioactive sphingolipid, serves as an important second messenger in cell signal transduction. Under stressful conditions, it can be generated from de novo synthesis, sphingomyelin hydrolysis, and/or the salvage pathway. The brain is rich in lipids, and abnormal lipid levels are associated with a variety of brain disorders. Cerebrovascular diseases, mainly caused by abnormal cerebral blood flow and secondary neurological injury, are the leading causes of death and disability worldwide. There is a growing body of evidence for a close connection between elevated ceramide levels and cerebrovascular diseases, especially stroke and cerebral small vessel disease.
Evidence strength: Preliminary to moderate mechanistic and observational evidence. No supplementation RCTs in humans have been identified for this indication.
5. Body Systems and Health Areas Associated with Ceramides
- Integumentary system (skin): Primary structural role in the stratum corneum barrier; clinical evidence for supplementation in hydration, barrier repair, atopic dermatitis, psoriasis, and aging skin. The strongest supplementation evidence exists in this category.
- Cardiovascular system: Specific ceramide species are established biomarkers for cardiovascular risk, myocardial infarction, and heart failure; mechanistic roles in endothelial dysfunction and atherogenesis are documented.
- Metabolic/endocrine system: Ceramide accumulation is associated with insulin resistance, type 2 diabetes, and metabolic syndrome; roles in pancreatic β-cell function have been described.
- Nervous system: Ceramides regulate neuronal membrane function, myelination, and apoptotic signaling; altered ceramide/S1P ratios are observed in Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS, and multiple sclerosis.
- Immune system: Ceramides regulate skin immune responses and participate in cytokine signaling; disrupted ceramide synthesis is downstream of inflammatory cytokine activity in atopic dermatitis and psoriasis.
- Hepatic system: De novo sphingolipid biosynthesis is activated by excess cellular palmitate and hyperlipidemic conditions in the liver. Ceramide accumulation is implicated in metabolic dysfunction-associated steatotic liver disease.
6. Dosage Forms and Doses Reported in Clinical Studies
The following dosages are reported as stated in the cited clinical sources; they should not be interpreted as recommended doses:
- Wheat polar lipid extract (Lipowheat/WEO), oral: 350 mg daily for 3 months in a study of 51 women with dry skin.
- Wheat polar lipid complex (WPLC), oral: 1.7 mg of glucosylceramides and 11.5 mg of digalactosyldiglycerides for 60 days in 60 volunteers.
- Konjac ceramide (phytoceramide), oral: 1.8 mg daily for 2 weeks in 50 children with moderate eczema.
- Rice-derived glucosylceramides, oral: 1.8 mg daily for 12 weeks in a hydration study.
- Topical ceramide formulations: Treatment creams and cleanser solutions containing ceramide EOP (ceramide-1), ceramide NP (ceramide-3), cholesterol, and linoleic acid in a physiological ratio of 3:1:1 have been used in skin barrier repair trials.
- Acetic acid bacteria–derived ceramide, oral: Used in a 12-week randomized, double-blind, placebo-controlled study for stratum corneum hydration improvement (published 2020, cited in multiple reviews).
Several studies evaluated ceramide supplementation in animals and humans, with results indicating that ceramide supplementation improves skin barrier, hydration, elasticity, and recovery upon induced disruption. Duration of supplementation in studies typically ranges from 2 weeks to 24 weeks, with all food supplements found to be safe throughout this research period.
7. Safety Considerations and Interactions
General Safety Profile
The evidence suggests that phytoceramide supplements are safe with no significant adverse effects reported. Phytoceramide supplements are generally considered safe based on available studies. In the wine lees–derived ceramide RCT, no adverse events related to the supplements were reported.
Wheat Allergy and Gluten Sensitivity
This is the most documented safety consideration for oral ceramic supplementation. Wheat-derived phytoceramides (Lipowheat) are lipid extracts that contain negligible protein and are generally considered gluten-free. However, individuals with celiac disease or severe wheat allergy may prefer rice-derived or sweet potato-derived ceramides as a precaution.
Pregnancy and Breastfeeding
Currently there is no data regarding the safety of oral ceramide supplements during pregnancy and breastfeeding. Animal studies on rats did not show complications during pregnancy or developmental abnormalities. Human safety data in these populations is absent.
Drug Interactions
There is no published evidence to suggest drug interactions or contraindications for phytoceramide supplements at doses used in clinical studies. This absence of documented interactions should be interpreted in the context of a limited published evidence base rather than as confirmation of safety across all pharmaceutical contexts.
Cardiovascular and Metabolic Caution: Endogenous Ceramides
While exogenous (supplemental) oral ceramides have not been shown to elevate circulating plasma ceramide species of pathological concern in safety trials, the broader mechanistic literature highlights that elevated endogenous ceramide species — particularly the long-chain varieties C16:0 and C18:0 — are associated with adverse cardiometabolic outcomes. An increasing number of studies have assigned a particularly deleterious role to ceramide accumulation in the development of insulin resistance and the deterioration of pancreatic β-cell function. De novo sphingolipid biosynthesis is activated by excess cellular palmitate and hyperlipidemic conditions. The clinical relevance of this to dietary phytoceramide supplementation at typical doses has not been directly studied.
Beta-Cell Function
Emerging research adds nuance to the question of ceramide and pancreatic function. Preserved de novo ceramide synthesis is required to maintain normal β-cell mass and thus insulin secretion in mice. Therapeutic approaches which seek to target this process systemically using pharmacological SPT2 inhibitors should thus be treated with caution. This bidirectional complexity — where both excess and deficiency of ceramide synthesis can be harmful — underlines the importance of species-specific and tissue-specific context.
Evidence Limitations
Studies on oral ceramides are extremely scarce, with most published data collected from in vivo and in vitro models. Despite emerging research supporting their efficacy, especially in improving skin hydration and potentially influencing metabolic markers, studies remain limited and predominantly involve small sample sizes. The overall safety and interaction profile for oral ceramide supplements is therefore based on a relatively small number of short-duration trials.
References
Go back